as 07-08-2024 4:00pm EST
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 7.1B | IPO Year: | N/A |
Target Price: | $94.33 | AVG Volume (30 days): | 1.8M |
Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.16 | EPS Growth: | N/A |
52 Week Low/High: | $45.50 - $84.89 | Next Earning Date: | 08-01-2024 |
Revenue: | $513,930,000 | Revenue Growth: | 65.45% |
Revenue Growth (this year): | 45.57% | Revenue Growth (next year): | 39.15% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
RIGGS RORY B | ITCI | Director | Jun 23 '24 | Sell | $75.57 | 4,462 | $337,193.34 | 116,600 | SEC Form 4 |
Neumann Mark | ITCI | EVP, Chief Commercial Officer | Mar 7 '24 | Sell | $66.95 | 4,496 | $301,007.20 | 29,700 | SEC Form 4 |
Neumann Mark | ITCI | EVP, Chief Commercial Officer | Mar 7 '24 | Sell | $66.37 | 8,636 | $573,171.32 | 34,196 | SEC Form 4 |
Neumann Mark | ITCI | EVP, Chief Commercial Officer | Mar 7 '24 | Sell | $66.86 | 1,313 | $87,787.18 | 29,700 | SEC Form 4 |
Neumann Mark | ITCI | EVP, Chief Commercial Officer | Mar 7 '24 | Sell | $65.92 | 1,729 | $113,975.68 | 31,013 | SEC Form 4 |
Neumann Mark | ITCI | EVP, Chief Commercial Officer | Mar 7 '24 | Sell | $65.11 | 4,303 | $280,168.33 | 32,742 | SEC Form 4 |
Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $66.38 | 31,958 | $2,121,372.04 | 1,059,063 | SEC Form 4 |
Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $66.93 | 8,754 | $585,905.22 | 1,050,309 | SEC Form 4 |
Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $64.80 | 14,541 | $942,256.80 | 1,056,333 | SEC Form 4 |
Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $65.90 | 4,128 | $272,035.20 | 1,052,205 | SEC Form 4 |
Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $66.81 | 1,590 | $106,227.90 | 1,050,615 | SEC Form 4 |
Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $67.33 | 306 | $20,602.98 | 1,050,309 | SEC Form 4 |
Halstead Michael | ITCI | EVP and General Counsel | Mar 7 '24 | Sell | $66.14 | 12,912 | $853,999.68 | 220 | SEC Form 4 |
Halstead Michael | ITCI | EVP and General Counsel | Mar 7 '24 | Sell | $66.81 | 220 | $14,698.20 | 0 | SEC Form 4 |
Halstead Michael | ITCI | EVP and General Counsel | Mar 7 '24 | Sell | $65.82 | 6,107 | $401,962.74 | 1,238 | SEC Form 4 |
Halstead Michael | ITCI | EVP and General Counsel | Mar 7 '24 | Sell | $66.70 | 1,238 | $82,574.60 | 0 | SEC Form 4 |
Durgam Suresh K. | ITCI | EVP, Chief Medical Officer | Mar 7 '24 | Sell | $66.34 | 3,728 | $247,315.52 | 18,892 | SEC Form 4 |
Durgam Suresh K. | ITCI | EVP, Chief Medical Officer | Mar 7 '24 | Sell | $66.86 | 2,722 | $181,992.92 | 16,170 | SEC Form 4 |
Durgam Suresh K. | ITCI | EVP, Chief Medical Officer | Mar 7 '24 | Sell | $65.06 | 2,179 | $141,765.74 | 21,336 | SEC Form 4 |
Durgam Suresh K. | ITCI | EVP, Chief Medical Officer | Mar 7 '24 | Sell | $65.89 | 872 | $57,456.08 | 20,464 | SEC Form 4 |
Durgam Suresh K. | ITCI | EVP, Chief Medical Officer | Mar 7 '24 | Sell | $66.96 | 661 | $44,260.56 | 19,803 | SEC Form 4 |
VAN NOSTRAND ROBERT L | ITCI | Director | Feb 27 '24 | Sell | $72.71 | 9,651 | $701,724.21 | 19,960 | SEC Form 4 |
VAN NOSTRAND ROBERT L | ITCI | Director | Feb 27 '24 | Sell | $73.14 | 10,349 | $756,925.86 | 9,611 | SEC Form 4 |
MARCUS JOEL S | ITCI | Director | Feb 26 '24 | Sell | $67.83 | 8,371 | $567,804.93 | 57,619 | SEC Form 4 |
MARCUS JOEL S | ITCI | Director | Feb 26 '24 | Sell | $69.07 | 17,658 | $1,219,638.06 | 39,961 | SEC Form 4 |
ITCI Breaking Stock News: Dive into ITCI Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
Investor's Business Daily
18 days ago
MT Newswires
18 days ago
MT Newswires
18 days ago
MT Newswires
18 days ago
MT Newswires
18 days ago
MT Newswires
18 days ago
Zacks
18 days ago
The information presented on this page, "ITCI Intra-Cellular Therapies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.